<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294826</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922AUS06T</org_study_id>
    <nct_id>NCT01294826</nct_id>
  </id_info>
  <brief_title>Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with&#xD;
      cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>1 cycle (1 cycle = 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient response rate to the AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression following treatment with AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients treated with AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <arm_group>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <description>Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.</description>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.</description>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer&#xD;
&#xD;
          -  KRAS wild type metastatic colorectal cancer&#xD;
&#xD;
          -  Progression of disease on at least 2 prior therapy to have included 5FU, or&#xD;
             oxaliplatin or bevacizumab or irinotecan&#xD;
&#xD;
          -  Prior treatment with cetuximab is allowed (full dose tolerated), provided that the&#xD;
             patient never required a dose reduction due to toxicities&#xD;
&#xD;
          -  Must have at least one measurable lesion&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy must be greater than 12 weeks&#xD;
&#xD;
          -  For women of childbearing potential, a negative pregnancy blood test must be obtained&#xD;
             less than 3 days prior to the first AUY922 infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Colorectal cancer with a KRAS mutation or in which the KRAS genotype status is unknown&#xD;
&#xD;
          -  Metastasis to the CNS&#xD;
&#xD;
          -  Prior treatment with any Hsp90 inhibitor compounds&#xD;
&#xD;
          -  Patients who received systemic anti-cancer treatment prior to the first dose of AUY922&#xD;
             within the following time frames:&#xD;
&#xD;
               -  Radiotherapy, conventional chemotherapy: within 2 weeks&#xD;
&#xD;
               -  Palliative radiotherapy: within 2 weeks&#xD;
&#xD;
               -  Nitrosoureas, monoclonal antibodies, such as trastuzumab and mitomycin: within 6&#xD;
                  weeks&#xD;
&#xD;
               -  Any continuous-dosing (i.e. daily dosing, every-other-day dosing,&#xD;
                  Monday-Wednesday-Friday dosing, weekly etc.) of systemic anti-cancer treatment&#xD;
                  for which the recover period is not known, or investigational drugs (i.e.&#xD;
                  targeted agents) within a duration of ≤ 5 half lives of the agent and their&#xD;
                  active metabolites (if any)&#xD;
&#xD;
          -  Treatment of therapeutic doses of coumadin-type anticoagulants. [Maximum daily dose of&#xD;
             2mg, for line patency permitted]&#xD;
&#xD;
          -  Known sensitivity to cetuximab&#xD;
&#xD;
          -  Unresolved ≥ grade 1 diarrhea&#xD;
&#xD;
          -  Malignant ascites that require invasive treatment&#xD;
&#xD;
          -  Concurrent medications that are substrates, inhibitors or inducers of CYP3A4, CYP2C8,&#xD;
             CYP2C9 and CYP2C19 and cannot be switched or discontinued or switched to an&#xD;
             alternative drug prior to commencing AUY922 dosing need special consideration on a&#xD;
             case by case basis&#xD;
&#xD;
          -  Major surgery ≤ 2 weeks prior to randomization or who have not recovered from such&#xD;
             therapy&#xD;
&#xD;
          -  Impaired cardiac function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Medical Center Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>HSP90 Heat-Shock Proteins</keyword>
  <keyword>EGFR protein, human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

